• Amanda Corley, Amanda J Ullman, Nicole Marsh, Larsen Emily N, Gabor Mihala, HarrisPatrick N APNAInfectious Disease Physician, Medical Microbiologist and NHMRC Early Career Fellow at The University of Queensland Centre for Clinical Research (UQCCR)., and Claire M Rickard.
• Adjunct Senior Research Fellow position with the AVATAR group at Menzies Health Institute QLD, Griffith University.
• Br J Nurs. 2020 Oct 22; 29 (19): S40-S46.

IntroductionPeripheral intravenous catheters (PIVCs) are widely used, but failure is unacceptably common with up to 69% failing before treatment is complete. PIVC securement reduces failure, but the optimal way to achieve this is unclear. Tapes and supplementary securement products are widely used, however rigorous testing of these to reduce PIVC failure remains unexplored.Methods And AnalysisIn adult medical-surgical wards at a tertiary hospital, this pilot randomized controlled trial tests standard care (bordered polyurethane dressing plus nonsterile tape over the extension tubing) against two securement interventions (intervention one: standard care plus two sterile tape strips over the PIVC hub; intervention two: intervention one plus a tubular bandage). Patients >18 years of age requiring a PIVC for >24 hours are eligible. Patients with laboratory-confirmed positive blood cultures within 24 hours of screening, known allergy to study products, current or high-risk of skin tear, or non-English speaking without interpreter are excluded. Sample size is 35 per trial arm, and central randomization is computer-generated with allocation concealed until entry. Patients and clinical staff cannot be blinded to treatment allocation. However, infection outcomes are assessed by a blinded investigator. Primary outcome is study feasibility. Secondary outcomes (PIVC failure, dwell time, skin adverse events, PIVC colonization, and cost) are compared between groups. Feasibility outcomes are reported descriptively.Ethics And Trial CommencementEthical approvals were received from Royal Brisbane and Women's Hospital (HREC/18/QRBW/44571) and Griffith University (2018/1000). Trial commencement was May 2019. Trial registration: ACTRN12619000026123.

11 keywords...

hide…